Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)

NCT04489420 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.

NCT NCT04489420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04489420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)
Lead sponsor
Celularity Incorporated
Phase
Phase 1
Overall status
Terminated
Start date
October 1, 2020
Completion date
August 10, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

analgesics, analgesics, non-narcotic, anti-infective agents, antiviral agents, astrocytoma, grade iv, cyclophosphamide, giant cell glioblastoma, glioblastoma multiforme, immunologic factors, immunosuppressive agents, molecular mechanisms of pharmacological action, peripheral nervous system agents, physiological effects of drugs, sensory system agents